ReviewCell reports methods2026
Spatial omics illuminates tumor heterogeneity.
Review in Cell reports methods, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intratumoral heterogeneity (ITH) is the coexistence of diverse cancer cell states, genotypes, and microenvironmental niches within a single tumor and is a major driver of therapeutic resistance and disease progression. While the clinical implications of ITH are well appreciated, conventional methods and models have been limited in resolving the spatial and functional complexity underlying ITH. Recent advances in single-cell and spatial omics, high-plex imaging, and in vivo CRISPR perturbation and lineage tracing now enable unprecedented, mechanistic dissection of tumor ecosystems. These technologies are beginning to reveal how cell-cell interactions, spatial organization, and clonal evolution collectively shape tumor behavior and treatment response. We review emerging methods for spatial proteomics and transcriptomics, functional genomics, and clonal tracing and highlight how their integration is redefining the study of ITH. We also discuss current challenges, including scalability, accessibility, and multimodal data integration, and opportunities as cancer biology enters the spatial era.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.